Healthcare >> CEO Interviews >> October 6, 2017

Interview with the CEO and President and the Chief Commercial Officer: CareDx, Inc. (NASDAQ:CDNA)

Maag, Peter
Peter Maag, Ph.D., is Chief Executive Officer and President of CareDx, Inc. Dr. Maag has over 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining CareDx, Dr. Maag was President of Novartis Diagnostics based in Emeryville, California. He headed the expansion of the unit with worldwide growth in its blood screening business and established new ventures in molecular diagnostics. Dr. Maag also led one of Novartis’ key affiliates as Country President, Germany, and lived in a dynamically growing and emerging market as Country President, Korea. At Novartis headquarters in Switzerland, he helped launch the Infectious Diseases franchise and served as the Head of Strategy for Novartis Pharmaceuticals. Prior to joining Novartis, Dr. Maag worked for six years at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Supporting various health care and high-tech companies in their growth efforts, he holds board and advisory positions at Phoenix and MolecularMD. Dr. Maag studied pharmaceutical sciences in Heidelberg and London, and received his Ph.D. from the University of Berlin, Germany. Profile
King, Sasha
Sasha King is Chief Commercial Officer of CareDx, Inc. Ms. King brings over 10 years of diagnostics and genetic testing experience. Most recently she worked in companion diagnostics marketing at Genentech and was a sales leader at Ariosa Diagnostics. While at Genentech, she worked on the launch of the first FDA-approved cell-free DNA test in oncology, the PD-L1 test launch and the Foundation Medicine partnership. Ms. King was an early member of the commercial team at Ariosa, a leader in the field of noninvasive prenatal testing — NIPT — which is now part of the Roche Group. She led the launch of their test into Asia Pacific and Canada. Ms. King previously worked at Fletcher Spaght, a life science consulting and venture capital fund. Ms. King received a Bachelor of Science in bioengineering from Massachusetts Institute of Technology and an MBA from Stanford Graduate School of Business. Profile
TWST: What is CareDx, Inc.?

Ms. King: CareDx is a company that focuses on creating clinically differentiated molecular diagnostics and high-value solutions for